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AbstrAct
Background There is no standardised method to 
investigate death as a patient safety indicator and we need 
valid and reliable measurements to use adverse events 
contributing to death as a quality measure.
Objective To investigate the contribution of severe 
adverse events to death in hospitalised patients and clarify 
methodological differences using the Global Trigger Tool 
method on all inpatient deaths compared with a sample of 
general hospitalised patients.
Method Retrospective records reviewing using the Global 
Trigger Tool method.
Results In 0.3% of hospital admissions, adverse events 
contribute to inpatient death. Patients who die in hospital 
have twice the rate of adverse events per 1000 patient 
days compared with general patients, 76.7 vs 36.5 
(p<0.001, RR 2.10, 95% CI 1.79 to 2.47). Patients dying in 
hospital experience seven times the rate of severe adverse 
events, 38.4% vs 5.2% (p<0.001, RR 2.10, 95% CI 1.79 
to 2.47). For 86 out of 377 inpatient deaths, the adverse 
event is so severe that it contributes to death. 27.9% of 
severe adverse events contributing to death originate in 
primary care. Lower respiratory infections (p<0.001, RR 
2.81, 95% CI 1.76 to 4.51), medication harm (p<0.001, RR 
5.21, 95% CI 3.04 to 8.94) and pressure ulcers (p=0.04, 
RR 2.23, 95% CI 1.03 to 4.85) are significantly more 
frequent for inpatient deaths than in the general sample of 
hospital patients.
Conclusions Patients dying in hospitals experience 
seven times the rate of severe adverse events. Reviewing 
all inpatient death by the Global Trigger Tool method 
discloses new valid and reliable data of severe adverse 
events contributing to death which otherwise would be 
undetected.
InTroducTIon
It has been estimated that adverse events 
due to medical error are the third leading 
cause of death in the USA.1 2 These estimates 
are based on studies of general hospitalised 
populations extrapolating that 0.6%–1.1% 
of admissions result in death due to adverse 
events.3 4 Other studies of inpatient deaths 
indicate that most types of adverse events 
occur more often in patients dying in hospi-
tals.5 6 This makes studying inpatient death 
in an efficient way to identify preventable 
adverse events and provide valuable informa-
tion in areas for improvement.6 A number 
of studies investigating mortality have found 
that only 0.5%–6.0% of adverse events 
contributing to death are preventable.7–10 
However, preventability is often difficult 
to determine and including this subjective 
judgement to mortality measures makes the 
measure even more uncertain.11 There is no 
standardised method of investigating death 
as a patient safety indicator, and uncertainty 
about the results has lead to an ongoing 
discussion about using estimated mortality 
from adverse events as a quality measure in 
patient safety.12 13 All the methods used have 
limitations such as extrapolation of results 
from samples, data not being based on a 
representative population or include subjec-
tive judgement of expectancy of death or 
preventability of adverse events. Despite these 
epidemiological controversies, death is the 
most severe consequence of an adverse event, 
and knowing the actual occurrence and type 
of adverse events contributing to death can 
be valuable to improve patient safety.
Retrospective record reviewing with 
trigger tools is a widely used methodology 
for a systematic review of adverse events in 
patient records, with high sensitivity and 
specificity compared with other methods.4 14 
Most trigger tool analyses are performed on 
samples of general hospitalised patients that 
involve few deaths and may therefore not 
provide valid epidemiological estimates of 
all patients dying in hospitals. Similar studies 
conducted on inpatient deaths are mainly 
based on samples and include judgement 
of preventability in assessing adverse events 
contributing to death.6–10 Instead of collecting 
data on many less severe adverse events that 
rarely result in death, an in-depth analysis of 
all hospital deaths could provide more valid 
and reliable data on severe adverse events 
that otherwise are undetected.
The aim of our study is to investigate the 
contribution of severe adverse events to death 
in hospitalised patients and clarify method-
ological differences using the Global Trigger 
Tool (GTT) method on all inpatient deaths 
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The study is a retrospective record review using the GTT 
method to compare adverse events in a sample of general 
hospitalised patients to review all inpatient deaths from 1 
January 2013 to 31 December 2013.
Setting
The study was performed at Nordland Hospital Trust in 
Norway. This is a public health trust consisting of three 
hospitals: one central and two smaller district general 
hospitals, with 524 beds in total. The three hospitals cover 
a population of approximately 136 000 people and offer 
most surgical and medical specialties.
Study population
The sample of general hospitalised patients includes 
1680 patient records. Ten patient records were randomly 
sampled twice monthly through block randomisation 
from the discharge list of seven functional units in the 
trust (surgery, orthopaedics, internal medicine, gynae-
cology/obstetrics, neurology/others and the district 
hospitals of Lofoten and Vesterålen). Patients under 
the age of 18, patients with a length of stay <24 hours or 
patients admitted primarily for psychiatric conditions or 
rehabilitation were excluded.
For the inpatient death sample, all 377 patients who 
died in the three hospitals during 2013 were included. 
Five patients under the age of 18 were excluded (figure 1).
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GTT review of a general sample
Nordland hospital trust since 2010 has routinely performed 
GTT reviews of general hospitalised patients. Our general 
sample consist of 1680 patient records routinely reviewed 
in 2013. Seven different teams performed a two-stage 
review according to the Norwegian version of The Insti-
tute of Healthcare Improvement GTT manual.15 16 Two 
nurses reviewed all records independently before they 
together reached consensus on presence, category and 
severity of adverse events. A physician then verified their 
findings.
GTT review of inpatient deaths
During 6 months in 2015, an independent team of two 
nurses and one physician reviewed the records of all 
hospital deaths during 2013. The review was done in 
the same way as the general sample, but the physician 
reached consensus together with the nurses. Then, two 
other physicians independently re-reviewed the records 
of adverse events contributing to death and agreed/disa-
greed on the adverse event, severity and type of harm. 
Finally, the physician from the primary review team 
and the verifying physicians discussed the findings and 
reached consensus.
definition and classification of adverse events
Adverse events were defined as: ‘Unintended physical injury 
resulting from or contributed to by medical care that requires 
additional monitoring, treatment or hospitalisation, or that 
results in death’.16 The severity of adverse events was cate-
gorised according to the National Coordinating Council 
for Medication Error Reporting and Prevention Index 
(NCC MERP index),17:
 ► Category E: temporary harm that required 
intervention.
 ► Category F: temporary harm that required initial or 
prolonged hospitalisation.
 ► Category G: permanent patient harm.
 ► Category H: intervention required necessary to 
sustain life.
 ► Category I: harm contributes to patient death.
Adverse events were categorised into 23 categories 
according to recommendations of the Norwegian GTT 
manual.15 For statistical purpose, the categories were 
aggregated into eight main categories in the study: hospi-
tal-acquired infections, surgical complications, bleeding/
thrombosis, patient fall/fracture, medication harm, 
obstetric harm, pressure ulcer and others. Table 1 gives an 
overview of the original categories and their aggregation. 
Adverse events associated with medical care given prior 
to or during hospitalisation were included to evaluate the 
total number of adverse events. For medication-related 
adverse events, the generic name was obtained. In addi-
tion, we obtained age, gender, length of stay, hospital, 
department, type of admission, primary and secondary 
diagnosis on discharge classified according to Interna-
tional Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10) system.
Statistical analysis
Demographic variables were compared using the Pear-
son’s Χ2 test and the Mann-Whitney U test. Incidence 
rates of adverse events, severities and categories of adverse 
events were compared using Poisson regression in gener-
alised linear models. Rates were calculated as adverse 
events per 1 000 patient days and as the percentage of 
admissions with one or more adverse events. Log patient 
days were used as an offset variable to compare rates per 
1000 patient days, and for admissions with adverse events, 
the offset variable was set to a fixed value of 0. In addi-
tion, we adjusted for the demographic variables such as 
age, gender, length of stay, hospital, department, type 
of admission and primary diagnosis. A p value <0.05 was 




Patients dying in the hospital are on average older than 
18.7 years, stay 5.2 days longer, are mainly emergency 
admissions and die more frequently in departments of 
internal medicine compared with patients discharged 
alive from hospital. Their three most common primary 
diagnoses are circulatory disorders, respiratory disorders 
and cancer (table 2).
comparison of adverse events
Analysing all inpatient deaths, adverse events contributed 
to death in 0.3% of all hospital admissions. Forty-six per 
cent of admissions for inpatient death experience one or 
more adverse events, compared with 16.3% of admissions 
in the general sample (p<0.001, RR 2.83, 95% CI 2.34 
to 3.43). Inpatient deaths have twice the rate of adverse 
events per 1000 patient days compared with the general 
sample, 76.7 vs 36.5 (p<0.001, RR 2.10, 95% CI 1.79 to 
2.47). Adjusting for demographic variables did not alter 
the result regarding the rate of adverse events per 1000 
patient days, 6.1 vs 3.1 (p<0.001, RR 1.94, 95% CI 1.58 to 
2.39).
Severity of adverse events
More severe adverse events (severity G, H and I) were 
identified for inpatient deaths than in the general 
sample, 38.4% vs 5.2%. Adjusted for demographic varia-
bles, admissions with adverse events and rates of adverse 
events per 1000 patient days for inpatient deaths are 
significantly higher for severe adverse events (severity 
G, H and I) (p<0.001, RR 24.0, 95% CI 11.47 to 50.13). 
There is no significant difference between the samples 
in rates of temporary adverse events (severity E and F) 
per 1000 patient days (p=0.138, RR 1.19, 95% CI 0.95 to 
1.50) (table 3). For inpatient deaths, 89 adverse events 
were primarily categorised as severity I. After verifica-
tion and consensus, two adverse events were dismissed, 
one changed severity and two changed types of harm, 
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for inpatient deaths compared with three adverse events 
in the general sample.
origin of adverse events
Nineteen per cent of adverse events originated in primary 
care for inpatient deaths compared with 11.6% in the 
general sample. For inpatient deaths, 27.9% of adverse 
events contributing to death were present on admis-
sion and originated in primary care. Inpatient deaths 
where the adverse event originate in primary care has a 
shorter length of stay (6.9 vs 15.8 days) and patients are 
on average 6.7 years older (84.4 vs 77.7 years) compared 
with inpatient deaths where adverse events originate after 
admission to hospital.
Type of adverse events
For inpatient death, we identify more healthcare-asso-
ciated infections than in the general sample, 42.4% vs 
33.0%. These are mainly lower respiratory infections, 
25.5% vs 10.5%. Inpatient deaths have more than five 
times the risk rate for adverse events related to medica-
tions than the general sample, 28.0% vs 8.3%, and twice 
the risk rate of developing pressure ulcers, 9.2% vs 3.4% 
(table 1).
Type of adverse events contributing to death
Lower respiratory infections with 47.7% and medication 
adverse events with 19.8% are the most common types of 
adverse events contributing to death among the 86 inpa-
tient deaths. Patients dying of lower respiratory infections 
are on average 82 years old and stay in hospital on average 
16.9 days. Patients acquiring the lower respiratory infec-
tion in primary care have a significantly shorter length of 
stay than those with a hospital-acquired infection, 6.0 vs 
22.5 days. Medication adverse events contribute to death 
for 17 of the inpatient deaths. Twelve of these patients 
have cancer as a primary or secondary diagnosis, whereof 
8 patients experience lethal complications after chemo-
therapy (table 1).
dIScuSSIon
Patients dying in hospitals differ from general hospital-
ised patients in several ways and experience seven times 
the rate of severe adverse events. GTT review of all inpa-
tient deaths and a sample of general hospitalised patients 
disclose different measures and perspectives that need to 
be considered using adverse events contributing to death 
as a valid and reliable quality measure.
The high ratio of adverse events for inpatient deaths 
in our study is similar to reviews of inpatient deaths done 








Mean age, years (SD) 58.8 (21.3) 77.5 (13.2)*
  18–102 18–102 18–102
Mean length of stay, days (SD)* 5.3 (5.9) 9.4 (11.7)*
  1–86 1–86 1–65
Gender, N (%)*
  Female 993 (59.1) 182 (44.9)
  Male 687 (40.9) 190 (51.1)
Type admission, N (%)*
  Acute 1211 (72.1) 364 (97.8)
  Planned 469 (27.9) 8 (2.2)
Hospital, N (%)*
  District Hospital Lofoten 240 (14.3) 56 (15.6)
  District Hospital Vesterålen 240 (14.3) 87 (23.4)
  Central Hospital Bodø 1200 (71.4) 227 (61.0)
Department, N (%)*
  Internal medicine 486 (28.9) 258 (69.4)
  Surgery 680 (40.5) 93 (25.0)
  Neurology 151 (9.0) 17 (4.6)
  Gynaecology 276 (16.4) 0
  Other departments 87 (5.2) 3 (0.8)
Primary diagnosis, N (%)*
  Infections 28 (1.7) 23 (6.2)
  Cancer 112 (6.7) 78 (21.0)
  Endocrine and haematological 86 (5.1) 6 (1.6)
  Neurological disorders 69 (4.1) 4 (1.1)
  Circulatory disorders 164 (9.8) 102 (27.4)
  Respiratory disorders 127 (7.6) 93 (25)
  Gastrointestinal disorders 144 (8.6) 25 (6.7)
  Skeletal and muscular 
disorders
21 (1,3) 3 (0.8)
  Urinary disorders 150 (8.9) 16 (4.3)
  Pregnancy and birth 231 (13.8) 0
  Damage and poisoning 170 (10.1) 16 (4.3)
  Unspecific symptoms 114 (6.8) 4 (1.1)
  Other disorders 264 (15.7) 18 (4.8)
Origin of adverse events, N (%)*
  Primary care 43 (11.6) 51 (19.0)
  Hospital 329 (88.4) 218 (81.0)
*Differences between groups for all characteristics, p<0.0001.












90 (33.4) 76 (28.3) 12 (4.5) 5 (1.9) 86 (32.0)
*Estimated differences per 1000 patient days using Poisson 
regression adjusted for demographic variables, p<0.001.
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in the Netherlands and a mortality review programme 
at Mayo Clinic in the USA.5 6 Nevertheless, our rates are 
higher than most other studies undertaken on general 
hospitalised patients.18–20 Even though we have a higher 
rate of adverse events contributing to death than other 
studies, adverse events contributing to inpatient deaths 
only account for 0.3% of all hospital admissions. This is 
lower than the 0.6%–1.3% of adverse events contributing 
to death extrapolated in previous general GTT studies.3 4 
This difference can be explained by large random vari-
ation when extrapolation is based on small numbers of 
adverse events contributing to death.
The high rate of adverse events in our study can partly 
be explained by the inclusion of adverse events origi-
nating in primary care, prior to admission. Patients dying 
in the hospital are a highly selected group of patients who 
are older, stay longer, are mainly emergency admissions 
and have a smaller range of primary diagnoses. From a 
previous study, we know that the risk of adverse events 
increases by 1.3% for every year increase in age and 5.1% 
for each day spent in the hospital.21 To have a representa-
tive population, we argue that measuring adverse events 
contributing to death should be based on inpatient 
deaths rather than generalisation of reviews of general 
hospitalised patients.
Even after adjusting rates of adverse events for demo-
graphic variables and primary diagnosis patients dying 
in hospitals have nearly twice the rate of adverse events 
per 1000 patient days. This indicates that rates of adverse 
events for inpatient deaths are influenced by other factors 
than just demographic characteristics. Many patients who 
die in hospitals are very ill and frail from underlying condi-
tions, making them more vulnerable to adverse events. It 
is rarely straightforward to establish that an adverse event 
has led directly to death. More often, the adverse event is 
one of many factors contributing to death. This does not 
diminish the importance of the event, but should instead 
encourage us to monitor and treat these patients with 
utmost care and caution.
Inpatient deaths experience seven times the rate of 
severe adverse events than found in the general GTT 
sample, and much greater rates compared with any 
other general GTT studies.18–20 Our general sample 
includes 8.7% of hospitalised patients in our trust, 
including 8.8% of the inpatient deaths. In our general 
sample, we found only three adverse events so severe 
that they contributed to death. This difference in the 
rate of adverse events contributing to death could 
be due to differences in sample size, and the fact 
that adverse events contributing to death are rare in 
general hospitalised patients. Then again, we find no 
significant difference in the rate of more common 
temporary adverse events (severity E and F) between 
the two samples. We argue that using the GTT method 
on a general hospitalised population is appropriate 
for identifying more common temporary adverse 
events, but the sample size is too small to provide reli-
able metrics of rarely occurring severe adverse events. 
By including all inpatients deaths, we avoid this 
sampling error. Our data demonstrate that reviewing 
all inpatient deaths can provide new valid and reliable 
data of severe adverse events which otherwise would 
be undetected.
To evaluate the total number of adverse events resulting 
from medical care, we included all adverse events asso-
ciated with care given prior to hospitalisation. Nearly 
one-third of adverse events contributing to death are 
present on admission and originates in primary care. 
These patients are on average older than other inpatient 
deaths and are often admitted from a nursing home. On 
average, they die within a week after admission and have 
a much shorter length of stay than patients acquiring 
their adverse event during hospitalisation. Our study does 
not investigate more deeply the circumstances around 
these admissions. Nevertheless, it raises questions as to 
whether the patient should have been admitted before 
or not admitted at all. Given that nearly one-third of 
patients are admitted with an adverse event contributing 
to death, it seems likely that the quality of care provided 
in primary care prior to admission to some degree affects 
the mortality measures of hospitals.
Baines et al have found that inpatient deaths have 
a lower proportion of surgical-related adverse events 
and a greater proportion of preventable hospital-ac-
quired infections.5 In our study, we find that health-
care-associated infections, medication harm and 
pressure ulcers are significantly more frequent among 
inpatient deaths than in the general sample. We 
identified a greater proportion of surgically related 
adverse events among inpatient deaths but adjusting 
for demographic variables, there is no significant 
difference between the samples.
We find that lower respiratory infections are the most 
common severe adverse event, occurring nearly three 
times as frequently and contributing to the death of 
nearly half of the inpatient deaths. Pneumonia is one 
of the most common infections requiring hospitalisa-
tion,22 and for one-third of these patients, pneumonia 
originating in primary care contributed to death. The 
prevalence of lower respiratory infections in our study 
may be accounted for by the inclusion of adverse events 
originating in primary care. Studies over the last decade 
have shown that healthcare-associated pneumonia, 
for instance, acquired in nursing homes, differs from 
community-acquired pneumonia in terms of pathogens, 
symptoms and prognosis.23 24 Delayed recognition of 
symptoms and delayed delivery of appropriate antimicro-
bial therapy result in excess mortality.25 These patients 
are older and have a greater burden of comorbidities, so 
patients at risk of healthcare-associated pneumonia are 
also those at increased risk of dying from their under-
lying conditions. This makes the causality of death hard 
to establish. Due to this, many clinicians have judged 
lower respiratory infections difficult to prevent. Judging 
preventability is a subjective process varying between 
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time.11 26 Healthcare-associated and hospital-acquired 
pneumonia are nevertheless important causes of severe 
adverse events that need to be considered when trying to 
improve patient safety. We argue that not judging prevent-
ability provides a more robust and reliable measurement 
of adverse events contributing to death.
Inpatient deaths have five times the risk for medica-
tion-related adverse events. Nearly all of the medication 
adverse events contributing to death were related to the 
treatment given in hospitals. More than 70% of severe 
medication adverse events contributing to death occur 
in patients with cancer, and most of these adverse events 
were related to lethal complications after chemotherapy. 
This makes medication adverse events primarily a safety 
issue in hospitals and confirms other studies identifying 
chemotherapy as a severe risk factor for adverse events in 
patients with cancer.27 28
Strengths and limitations
This study has the standard limitations of retrospec-
tive patient record reviewing such as information 
bias and poor to moderate reliability. The review 
process was performed in a slightly different way for 
the two samples. The step where the physician comes 
to consensus with the nurses for the inpatient death 
sample can have influenced what was considered an 
adverse event and its severity. Hindsight bias could 
be another limitation. Knowing the outcome and its 
severity on the judgement of causation could influ-
ence the judgement.29 The outcome of inpatient 
death is death, compared with the general sample 
where the outcome and the severity of the adverse 
events are largely unknown at the start of the review 
process. Hindsight bias may have led to an overesti-
mation of the number and severity of adverse events 
for the inpatient death sample. To reduce the risk of 
hindsight bias, we added an extra step in the reviewing 
process of the inpatient death sample, where two inde-
pendent physicians reviewed and discussed the most 
severe adverse events contributing to death once more 
before consensus was reached. The good correlation 
between the reviewing physicians could indicate a low 
effective hindsight bias, and we argue that adding this 
extra step increases the validity of the results for the 
inpatient deaths. Another strength of our study is that 
all inpatient deaths in our hospital trust are included, 
avoiding selection bias and providing a more accurate 
measurement of the contribution of adverse events to 
death in hospitalised patients.
concluSIon
Patients dying in hospitals differ in several ways from a 
general hospitalised population and experience seven 
times the rate of severe adverse events. GTT review of 
general hospitalised patients primarily identifies more 
common temporary adverse events, while a review of 
all inpatient deaths provides a new valid and reliable 
measurement of severe adverse events contributing to 
death that otherwise would be undetected. Demographic 
differences and sample size argue that mortality estimates 
of adverse events rarely contributing to death should 
not be extrapolated from GTT reviews of small general 
samples of hospitalised patients.
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